Curvebeam AI (ASX:CVB) — Material Events
ASX:CVB · 15 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
CurveBeam AI Accelerates Growth with China JV and $6.5m Capital RaiseMedium
CurveBeam AI Q1 FY26: 33% PO growth, A$6.5m placement, China JV inked, FDA clearance targeted mid-2026
30 Oct 2025
·Quarterly Company Call / Investor Presentation
·85
CurveBeam AI Raises A$6.5M, Advances Growth with Vendor Financing and China Deal TalksMedium
CurveBeam AI raises A$6.5M, secures €10M vendor financing, advances surgical robot validation, and pursues China partnership
29 Sept 2025
·Capital Raising
·85
CurveBeam AI Accelerates Growth with Record Sales and New Financing DealMedium
CurveBeam AI posts record Q4 receipts, advances HiRise™ validation and FDA clearance, secures A$18m financing facility
30 July 2025
·Appendix 4C & Quarterly Activity Report
·85
CurveBeam AI Secures A$4 Million Strategic Investment to Fuel China ExpansionMedium
CurveBeam AI secures A$4 million strategic investment from Chinese orthopaedic device subsidiary
2 Feb 2026
·Strategic Investment Announcement
·85
CurveBeam AI Raises A$6.5m to Accelerate HiRise™ CT Scanner ExpansionMedium
CurveBeam AI raises A$6.5m to expand HiRise™ CT scanner market with Stryker partnership and China deal in progress
29 Sept 2025
·Investor Presentation and Capital Raising
·85
CurveBeam AI Secures $10M China Investment Backed by WEGO OrthopaedicsMedium
CurveBeam AI Secures China ODI Approval for A$10M Strategic Investment with WEGO Orthopaedics
7 Jan 2026
·Strategic Investment Announcement
·85
CurveBeam AI Secures $4M Milestone, Advances FDA Filing and Device ValidationMedium
CurveBeam AI secures $4m China milestone, advances FDA filing, reports stable device orders and improved cash flow in Q2 FY26
29 Jan 2026
·Appendix 4C & Quarterly Activity Report
·80
CurveBeam AI Accelerates Growth with China Deal and $6.5M Capital RaiseMedium
CurveBeam AI boosts device orders, secures A$6.5m placement, and finalizes China JV with A$10m investment
30 Oct 2025
·Appendix 4C & Quarterly Activity Report
·80
CurveBeam AI Doubles Revenue and Cuts Losses in FY25 Despite Device Validation DelaysMedium
CurveBeam AI posts 86% revenue growth and narrows FY25 net loss by 27%
28 Aug 2025
·Preliminary Final Report
·80
CurveBeam AI Reports 85% Revenue Surge Amid Ongoing Losses and Validation HurdlesMedium
CurveBeam AI reports 85% revenue growth, reduced loss, raises $11.58M, but flags going concern uncertainty
28 Aug 2025
·Appendix 4E Preliminary Final Report
·75
CurveBeam AI Posts 18% Purchase Order Growth and Nears $18M Financing DealMedium
CurveBeam AI posts 18% PO growth, positive cash flow, and nears A$18m financing deal
30 July 2025
·Quarterly Investor Presentation
·75
CurveBeam AI Secures $4M Milestone, Advances FDA and China Regulatory PathwaysMedium
CurveBeam AI advances regulatory and commercial milestones with $4M milestone payment pending and FDA submission underway
29 Jan 2026
·Quarterly Company Call Presentation
·75
CurveBeam AI Navigates Regulatory Delays Amid China JV and Clinical AdvancesMedium
CurveBeam AI Q3 FY26: Five POs, Regulatory Progress, New Director, China JV Advances
30 Apr 2026
·Quarterly Company Update
·75
No articles in this tier for the last 12 months.
Market Mentions
3
- appeared in market wrap coverage
These are market wrap articles where Curvebeam AI (ASX:CVB) was mentioned. They reflect broader market coverage, not company-specific announcements.
Market Wrap - Week 6 (2 Feb -> 6 Feb) 2026
7 Feb 2026
Healthcare Wrap - Week 6 (2 Feb -> 6 Feb) 2026
7 Feb 2026
Healthcare Wrap - Week 5 (26 Jan -> 30 Jan) 2026
31 Jan 2026